Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

doctors and pharmacists across the US are struggling to get their hands on Eli Lilly & Co.’s powerful new obesity drug ...

Asian shares traded mixed Tuesday, echoing Wall Street trading, where gains for oil-and-gas producers helped offset drops for Nvidia and other Big Tech companies. Japan’s ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly has turned to a biotechnology startup for help building its pipeline of cancer drugs, agreeing on ...

Eli Lilly has lined up another deal in the radiopharmaceutical ... is a “largely unexplored” class for radiopharma. The San Diego-based biotech is tasked by Lilly with generating a pipeline ...

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes." ...

AnaptysBio (NASDAQ:ANAB), which is advancing an arthritis therapy similar to Eli Lilly's (NYSE ... With its Q2 2024 results ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after ...